Introduction

In 2014 the National Audit of Schizophrenia identified that ELFT was a comparatively low prescriber of Clozapine, so the AOS team decided to launch a QI project to tackle this issue.

The team identified key drivers, as shown in the driver diagram in figure 2 below, and concluded that a particularly important issue to resolve was the lack of a clear process for identifying when people have Treatment Resistant Schizophrenia; and so when they may be suitable for Clozapine.

To address this, they developed, through multiple PDSAs, the “Assessment Checklist for Treatment Resistant Schizophrenia”, as shown in figure 1.

Use of this new process has enabled AOS to increase identification of TRS in this caseload to over 75%, which has also resulted in small increases in number of people on Clozapine and reduction in polypharmacy.

City and Hackney is now scaling-up the learning and approach to this work to two inpatient wards (Conolly and Ruth Seifert) and South CMHT.

Progress with Scale-up

• Scale-up sites, Ruth Seifert, Conolly Ward and South CMHT are currently developing their strategy and taking forwards their first PDSAs.

• All scale-up sites developed a basic driver diagram together and this is being refined further by each test site to ensure it reflects their own specific circumstances and challenges.

• Figure 6 shows the specific driver diagram for South CMHT.

• The project team has identified that a key issue for them is to have an effective trigger/reminder which prompts doctors in the community to think of doing the TRS assessment when this is required. Their first PDSA is testing whether using the phrase “Psychotic on Antipsychotics” enables them to do this (see Figure 5 below).

Next steps

Over the next month we aim to fully set up all project measures for each scale-up site and take forward further PDSAs. Particularly we are keen to start working on the Information for Service Users driver; firstly by developing our understanding of what service users who now use Clozapine feel is important to know and understand when considering Clozapine and how we can best support them.